

Drug Manufacturers Raise Prices for 648 Brands In 2020 Through September

16 Brands Increase 10 Percent or More with Mytesi (Napo Pharmaceuticals, Inc) Leading the Way at 230 Percent

FAYETTEVILLE, NEW YORK, UNITED STATES, October 15, 2020


/EINPresswire.com/ -- With rising drug prices being one of the biggest health concerns in the United States in 2020, more than 200 drug manufacturers have raised prices on 648 brands with an average price increase of 5.9% through September 2020. This comes

in almost one percent lower than last year during the same time period where 664 brands had an average price increase of 6.7%. Among brands taking price increases this year include Nitro-Dur (Ingenus), used to prevent angina, up 50.0%, Nerlynx (Puma Biotechnology), used to treat a certain type of early-stage breast cancer, up 20.8%, and Fanapt (Vanda Pharmaceuticals), used to treat schizophrenia in adults, up 17.7%. Through September, sixteen brands have had price increases of at least 10.0% (see chart). Overall, price increases for the first nine months of 2020 range from a low of 0.6% for Tisseel VHSD (Baxter Healthcare) to 230.0% for Mytesi.

Back in May of this year the manufacturer of Mytesi, Jaguar Health Inc, was asked by Representative Carolyn Maloney, the chair of the House Oversight Committee, and Representative Jackie Speier, a fellow Democratic committee member, to reverse recent price hikes and provide information on the price increases.

Octagam (Octapharma USA), indicated for the treatment of primary immune deficiency disorder, took a price increase of 12 percent back at the beginning of February. In May, the U.S. Food and Drug Administration approved the investigational new drug application for a phase three clinical trial of Octagam on the efficacy and safety for therapy in COVID-19 patients with severe disease progression.

It is important to note, these price changes affect list prices, or Wholesale Acquisition Cost* (WAC), that are set by the drug manufacturers without taking into account rebates, insurance,



and other discounts that may be available.

Source

[AnalySource](#)® as of October 13, 2020 - Reprinted with permission by [First Databank, Inc.](#) All rights reserved. © 2020

* First Databank, Inc Drug Pricing Policy: <https://www.fdbhealth.com/drug-pricing-policy>

About DMD America, Inc

AnalySource® is a registered trademark and drug pricing data solution service of DMD America, Inc. Since 1996, data has been made available in cooperation with First Databank, Inc., a subsidiary of the Hearst Corporation. Our service is licensed by subscription, with global clients, including biotech, pharmaceuticals, government agencies, consultancies, academia, and more.

About First Databank (FDB)

First Databank (FDB) is the leading provider of drug and medical device knowledge that helps healthcare professionals make precise decisions. We empower our information system developer partners to deliver valuable, useful, and differentiated solutions used by millions of clinicians, business associates, and patients every day. For more than four decades, our medical knowledge has helped improve patient safety, operational efficiency, and healthcare outcomes. For a complete look at our solutions and services, please visit www.fdbhealth.com.

Eric Tedford

DMD America

+1 315-671-4208

[email us here](#)

Visit us on social media:

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/528317325>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.